ANAB Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Anaptysbio, Inc had $235M of revenue in fiscal 2025, up 157.0% on the year before. Over five years, revenue changed +25.6% a year on average.
Last close Β· Oct 23, 2026
$48.73
1.3%Hi! I read Anaptysbio, Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+157.0%
Yes. Sales grew 157.0% last year.
Does it make a profit?
β5.6%
No. It lost money last year.
Does profit turn into cash?
8.4%
Partly. 8.4% of sales ends up as free cash.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Anaptysbio, Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 3, 2026
Tuesday Β· in 8 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Sep 21, 2026 | Q2 '26 | After the market closes | 10-KT β |
| May 12, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 9, 2026 | Q4 '25 | After the market closes | 8-K β |
| Nov 4, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 6, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 5, 2025 | Q1 '25 | After the market closes | 8-K β |
| Feb 27, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 5, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Anaptysbio, Inc had $235M of revenue in fiscal 2025, up 157.0% on the year before. Over five years, revenue changed +25.6% a year on average. Its operating margin was 96.7%, up 24.2Β pts: of every 100 in sales, about 97 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Anaptysbio, Inc lost $13.2M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $19.6M in fiscal 2025, 8.4% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Anaptysbio, Inc returned $68.6M to shareholders in fiscal 2025, 350% of free cash flow. The diluted share count rose 2.3%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Anaptysbio, Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $548M | $441M | $391M | $285M | $212M |
| Current ratio | 34.4x | 17.2x | 10.9x | 9.5x | 9.1x |
| Quick ratio | 34.4x | 17.2x | 10.9x | 9.5x | 9.1x |
| Total assets | $643M | $610M | $452M | $484M | $364M |
| Total liabilities | $287M | $348M | $364M | $413M | $327M |
| Shareholders' equity | $356M | $262M | $88.1M | $70.9M | $37.2M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Anaptysbio, Inc passes 4 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 7 | 2 / 7 | 2 / 7 | 4 / 7 | 2 / 7 | 1 / 7 | 3 / 7 | 3 / 7 | 4 / 7 |
| Accruals ratio | 7.7% | β5.4% | β3.1% | β5.9% | β1.4% | β2.2% | β8.8% | β8.1% | β2.1% | β7.8% |
| Altman Z'' | 1.93 | 18.15 | 26.06 | 15.85 | 24.50 | 4.57 | 1.64 | β1.26 | 1.22 | 3.00 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $16.7M | $10.0M | $5.0M | $8.0M | $75.0M | $63.2M | $10.3M | $17.2M | $91.3M | $235M |
| Research and development | $15.4M | $29.4M | $56.2M | $99.3M | $80.0M | $98.5M | $88.8M | $132M | $164M | $136M |
| Operating income | β$3.0M | β$28.8M | β$66.7M | β$107M | β$23.9M | β$56.8M | β$115M | β$164M | $66.2M | $227M |
| Interest expense | $0.5M | $1.8M | $1.7M | $1.0M | $0.0M | $0.0M | β | β | β | β |
| Pretax income | β$4.3M | β$30.1M | β$61.8M | β$97.5M | β$19.9M | β$57.8M | β$129M | β$164M | $31.1M | $162M |
| Income tax | $0.0M | $0.0M | β$0.2M | β$0.2M | $0.0M | $0.0M | $0.0M | β$0.0M | $0.2M | $0.8M |
| Net income | β$4.3M | β$30.1M | β$61.7M | β$97.3M | β$19.9M | β$57.8M | β$129M | β$164M | β$145M | β$13.2M |
| Net income to common | β$4.3M | β$30.1M | β$61.7M | β$97.3M | β | β | β | β | β | β |
| Diluted EPS | β$1.62 | β$1.52 | β$2.50 | β$3.60 | β$0.73 | β$2.11 | β$4.57 | β$6.08 | β$4.92 | β$0.44 |
| Diluted shares | 0.00B | 0.02B | 0.02B | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B | 0.03B |
| Cash flow | ||||||||||
| Cash from operations | β$9.0M | β$19.4M | β$48.5M | β$69.5M | β$14.2M | β$45.9M | β$73.6M | β$121M | β$135M | $19.7M |
| Capital expenditure | $0.1M | $0.3M | $1.1M | $0.8M | $0.6M | $1.4M | $0.4M | $0.8M | $0.4M | $0.1M |
| Free cash flow | β$9.1M | β$19.7M | β$49.6M | β$70.3M | β$14.7M | β$47.3M | β$74.0M | β$122M | β$136M | $19.6M |
| Depreciation and amortization | $0.2M | $0.2M | $0.3M | $0.5M | $0.6M | $0.6M | $0.7M | $0.7M | $0.0M | $0.0M |
| Stock-based compensation | $1.2M | $4.4M | β | β | β | $15.3M | $27.4M | $33.2M | $7.2M | $3.8M |
| Share buybacks | $0.0M | $0.0M | $0.0M | β | β | $0.0M | $0.0M | $50.0M | $0.5M | $68.6M |
| Dividends and buybacks | $0.0M | $0.0M | $0.0M | β | β | $0.0M | $0.0M | $50.0M | $0.5M | $68.6M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $51.2M | $248M | $427M | $374M | $394M | $548M | $441M | $391M | $285M | $212M |
| Current assets | $58.2M | $253M | $434M | $378M | $397M | $554M | $447M | $407M | $432M | $350M |
| Current liabilities | $5.7M | $14.1M | $21.8M | $29.5M | $19.8M | $16.1M | $26.1M | $37.4M | $45.4M | $38.6M |
| Property and equipment, net | $0.5M | $0.7M | $1.4M | $1.6M | $1.8M | $2.3M | $2.1M | $2.1M | $0.1M | $0.1M |
| Total assets | $62.2M | $329M | $509M | $435M | $417M | $643M | $610M | $452M | $484M | $364M |
| Total liabilities | $100M | $21.8M | $22.6M | $30.2M | $19.8M | $287M | $348M | $364M | $413M | $327M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$38.2M | $308M | $486M | $405M | $397M | $356M | $262M | $88.1M | $70.9M | $37.2M |
| Margins | ||||||||||
| Operating margin | β18.1% | β287.8% | β1,334.4% | β1,342.9% | β31.8% | β89.9% | β1,119.4% | β958.3% | 72.5% | 96.7% |
| EBITDA margin | β16.7% | β286.0% | β1,328.1% | β1,336.5% | β31.1% | β89.0% | β1,112.9% | β954.5% | 72.5% | 96.7% |
| Net margin | β25.5% | β300.7% | β1,233.1% | β1,216.7% | β26.6% | β91.5% | β1,251.3% | β953.7% | β159.1% | β5.6% |
| FCF margin | β54.4% | β197.3% | β991.4% | β879.0% | β19.6% | β74.8% | β718.9% | β708.8% | β148.7% | 8.4% |
| Returns | ||||||||||
| Return on capital employed | β5.4% | β9.1% | β13.7% | β26.5% | β6.0% | β9.1% | β19.7% | β39.6% | 15.1% | 69.7% |
| Return on equity | β | β22.3% | β15.5% | β21.8% | β5.0% | β15.3% | β41.6% | β93.4% | β182.7% | β24.5% |
| Return on assets | β6.8% | β15.4% | β14.7% | β20.6% | β4.7% | β10.9% | β20.5% | β30.8% | β31.0% | β3.1% |
| Return on tangible equity | β | β9.8% | β12.7% | β24.0% | β5.0% | β16.2% | β49.1% | β185.7% | β204.9% | β35.6% |
| Growth | ||||||||||
| Revenue growth | β | β40.1% | β50.0% | 60.0% | 837.5% | β15.8% | β83.7% | 66.8% | 432.0% | 157.0% |
| Share count change | β | 650.2% | 24.7% | 9.7% | 0.9% | 0.5% | 2.7% | β4.4% | 9.7% | 2.3% |
| Financial health | ||||||||||
| Interest coverage | β6.6x | β16.2x | β40.4x | β103.2x | β | β | β | β | β | β |
| Current ratio | 10.2x | 17.9x | 19.9x | 12.8x | 20.0x | 34.4x | 17.2x | 10.9x | 9.5x | 9.1x |
| Quick ratio | 10.2x | 17.9x | 19.9x | 12.8x | 20.0x | 34.4x | 17.2x | 10.9x | 9.5x | 9.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.3% | 2.9% | 21.3% | 10.1% | 0.8% | 2.2% | 3.5% | 4.7% | 0.4% | 0.0% |
| Stock comp / revenue | 7.0% | 43.8% | β | β | β | 24.3% | 265.9% | 193.5% | 7.9% | 1.6% |
| Payouts / FCF | β | β | β | β | β | β | β | β | β | 350.0% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 2.0 | 2.0 | 4.0 | 2.0 | 1.0 | 3.0 | 3.0 | 4.0 |
| Altman Z'' | 1.9 | 18.1 | 26.1 | 15.8 | 24.5 | 4.6 | 1.6 | β1.3 | 1.2 | 3.0 |
| Accruals ratio | 7.7% | β5.4% | β3.1% | β5.9% | β1.4% | β2.2% | β8.8% | β8.1% | β2.1% | β7.8% |
Source: SEC EDGAR XBRL filings (CIK 0001370053). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
